Stockscreener 앱 받기
4.44
3.27%
-0.15
시장 영업 전:
4.47
0.03
+0.68%
전일 마감가:
$4.59
열려 있는:
$4.64
하루 거래량:
2.54M
Relative Volume:
0.58
시가총액:
$722.29M
수익:
$400.57M
순이익/손실:
$9.21M
주가수익비율:
111.00
EPS:
0.04
순현금흐름:
$146.36M
1주 성능:
-1.00%
1개월 성능:
+9.36%
6개월 성능:
+430.91%
1년 성능:
+136.17%
1일 변동 폭
$4.28
$4.65
1주일 범위
$4.28
$4.905
52주 변동 폭
$0.5271
$5.78
아이언우드 제약 Stock (IRWD) Company Profile
명칭
Ironwood Pharmaceuticals Inc
전화
617-621-7722
주소
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
4.44 | 746.69M | 400.57M | 9.21M | 146.36M | 0.04 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
아이언우드 제약 Stock (IRWD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-04-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | 개시 | Leerink Partners | Market Perform |
| 2024-08-08 | 다운그레이드 | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | 개시 | Craig Hallum | Buy |
| 2023-12-14 | 개시 | Wells Fargo | Overweight |
| 2023-11-09 | 개시 | Jefferies | Buy |
| 2023-09-28 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-02 | 개시 | CapitalOne | Overweight |
| 2022-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-09-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | 개시 | Northland Capital | Outperform |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2018-11-07 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-07-23 | 개시 | H.C. Wainwright | Sell |
| 2018-05-09 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2017-07-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2017-05-03 | 개시 | Wells Fargo | Outperform |
| 2017-04-07 | 재확인 | Mizuho | Buy |
| 2017-02-22 | 재확인 | Barclays | Equal Weight |
| 2016-11-04 | 재확인 | Mizuho | Buy |
| 2016-10-24 | 재확인 | Wedbush | Neutral |
| 2016-10-10 | 재확인 | Mizuho | Buy |
| 2016-09-27 | 재확인 | WallachBeth | Hold |
모두보기
아이언우드 제약 주식(IRWD)의 최신 뉴스
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 5.7%Here's What Happened - MarketBeat
3 Stocks Trading Near $5 With Massive Earnings Upside - Investing.com
Aug Intraday: Can CHARR expand into new marketsJuly 2025 Momentum & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
What Recent Medicare Pricing Terms Mean For The Ironwood Pharmaceuticals (IRWD) Investment Story - Yahoo Finance
Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption? - Yahoo Finance
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Craig-Hallum Bullish on Ironwood Pharmaceuticals (IRWD), Keeps Buy Rating - Finviz
Craig-Hallum bullish on Ironwood Pharmaceuticals (IRWD), keeps buy rating - MSN
11 Cheap Hot Stocks to Invest In Right Now - Insider Monkey
Day Trade: What is the PEG ratio of RRBIWeekly Trade Summary & High Win Rate Trade Tips - baoquankhu1.vn
Nasdaq Moves: Is GGNPRB attractive at current valuationGDP Growth & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Ironwood Pharmaceuticals stock soars on strong 2026 guidance By Investing.com - Investing.com Nigeria
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) Fits the Minervini High-Growth Momentum Trend Template - Chartmill
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
Can Ironwood Pharmaceuticals Inc. outperform in the next rallyJuly 2025 Price Swings & Detailed Earnings Play Strategies - mfd.ru
Does Ironwood Pharmaceuticals Inc. stock benefit from AI growth2025 Market Trends & Daily Volume Surge Signals - mfd.ru
Aug Gainers: Can Ironwood Pharmaceuticals Inc outperform in the next rally2025 Dividend Review & Free Reliable Trade Execution Plans - baoquankhu1.vn
EPS Watch: Can Ironwood Pharmaceuticals Inc maintain sales growthMarket Volume Summary & Technical Entry and Exit Tips - baoquankhu1.vn
Is Ironwood Pharmaceuticals Inc. stock risky to hold now2025 Analyst Calls & Weekly Top Performers Watchlists - mfd.ru
Zacks.com featured highlights include IPG Photonics, Ironwood and Science Applications - Yahoo Finance
Jobs Data: Can Ironwood Pharmaceuticals Inc maintain sales growthSwing Trade & Capital Efficiency Focused Ideas - baoquankhu1.vn
Zacks Research Issues Optimistic Forecast for IRWD Earnings - MarketBeat
Returns Recap: Can Ironwood Pharmaceuticals Inc. stock double in the next year2025 Earnings Impact & Daily Momentum Trading Reports - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Up 8.4%Here's Why - MarketBeat
Best Penny Stocks To Watch TodayJanuary 2nd - MarketBeat
Zacks Research Has Positive Outlook for IRWD Q4 Earnings - MarketBeat
Ironwood Pharma Stock Soars After FDA Grants Approval For Irritable Bowel Syndrome Drug In Pediatric Patients - MSN
Weekly Earnings: Is Ironwood Pharmaceuticals Inc forming a breakout patternJuly 2025 Short Interest & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Aug Weekly: Is Ironwood Pharmaceuticals Inc forming a breakout patternPortfolio Profit Report & Verified Technical Trade Signals - baoquankhu1.vn
Promising Pharmaceutical Stocks To ConsiderJanuary 2nd - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 5.4%Here's Why - MarketBeat
Chipmakers Recap: Is Ironwood Pharmaceuticals Inc affected by consumer sentimentJuly 2025 Spike Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Insider Sell: Should you avoid Ironwood Pharmaceuticals Inc. stock right nowMarket Sentiment Review & Entry Point Strategy Guides - baoquankhu1.vn
Ironwood Pharmaceuticals (IRWD) Price Target Increased by 94.00% to 4.95 - Nasdaq
Growth Recap: Does Ironwood Pharmaceuticals Inc have declining or rising EPSWeekly Market Summary & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Up 10.7%Here's What Happened - MarketBeat
Winners Losers: Is Ironwood Pharmaceuticals Inc affected by consumer sentimentJuly 2025 Catalysts & Weekly Stock Performance Updates - baoquankhu1.vn
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2026-01-10 17:20:03 - Улправда
Ironwood Pharma resolves Ferring dispute, amends license terms - MSN
Ironwood stock rises 27% on upbeat revenue guidance for 2026 - MSN
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance
Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating - MarketBeat
5 Small Drug Stocks to Buy as Industry Recovery Picks Up - Yahoo Finance
Ironwood hits 52-week high as AbbVie-partnered Linzess boosts 2026 outlook - MSN
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Upgraded by Craig Hallum - MarketBeat
Why did Ironwood Pharmaceuticals stock skyrocket today? - MSN
There's No Escaping Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Muted Revenues Despite A 32% Share Price Rise - 富途牛牛
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Shares Bounce 32% But Its Business Still Trails The Industry - simplywall.st
Citizens Upgrades Ironwood Pharmaceuticals (IRWD) - Nasdaq
Craig-Hallum Boosts Ironwood (IRWD) Rating with Optimistic Outlo - GuruFocus
아이언우드 제약 (IRWD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
0.15%
자본화:
|
볼륨(24시간):